You are here

Epinastine Shows Rapid Efficacy, Control of Ocular Allergy Symptoms

SAN DIEGO, April 29 /PRNewswire/ -- Data from a new study to evaluate the efficacy of epinastine (HCl 0.05%) were presented today at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Ft. Lauderdale, Fla. Epinastine is the most recent addition to a new generation of ocular allergy treatments that features a multi-action mechanism consisting of topical ophthalmic antihistamine, with mast cell-stabilizing and anti-inflammatory properties.

"Ocular allergy affects approximately 22 million Americans. Symptoms such as itching, redness, and swelling often cause significant discomfort and in some cases can lead to severe complications and even blindness," said lead researcher Dr. Mitchell H. Friedlaender, Head of the Division of Ophthalmology and Director of the Laser Vision Center at Scripps Clinic in La Jolla, CA. "Due to its unique mechanism of action, epinastine not only reduced symptoms of discomfort, but also appearance-related symptoms, which often impact patients' daily activities and self esteem."

Study Results

The single-center, randomized study used the conjunctival allergen challenge model (CAC), and examined 30 women 18-75 years old, who had a history of allergic conjunctivitis.

In the onset efficacy evaluation, instilling epinastine five minutes prior to allergen challenge provided significant relief of itching and redness (erythema) compared with vehicle. In the duration of efficacy assessment, epinastine relieved itching for at least 12 hours after treatment. Using advanced medical imaging technology that highlights changes in facial topography, epinastine was shown to prevent swelling (edema) visibly.

About Epinastine

Recent advances in the treatment of ocular allergy have led to the development of innovative therapies such as epinastine that target multiple phases of the allergic cascade. This multi-action treatment not only blocks release of histamine, but also stabilizes mast cells, thereby preventing inflammation, a critical component of allergy treatment. Data suggest that epinastine's mechanism of action features a greater affinity for H2 receptors than other antihistamine/mast cell stabilizers and since H2 receptors are more commonly found on blood vessels than H1 receptors, epinastine could potentially be more effective in the relief of swelling than other dual-action agents.

About Ocular Allergy and Conjunctivitis

Ocular allergy symptoms are present when the body's immune system becomes highly sensitized to various allergens and the patient's immune system over-reacts, causing a "cascading effect" which then leads to long-lasting symptoms -- known as allergic conjunctivitis.

While ocular allergy is considered to be a nuisance, allergic conjunctivitis can be debilitating for many patients. In extreme cases, certain inflammatory proteins are released as the body's immune system continues to react. Over time, these proteins can cause ulcers to form in the cornea.

It is estimated that 80 million Americans suffer from allergies. Ocular allergy patients make up approximately one-quarter of all allergy sufferers. Ocular allergy symptoms are often caused by exposure to many of the same allergens that affect the respiratory system, including the sinuses, nose and lungs.

Seasonal allergic conjunctivitis, the most serious manifestation of ocular allergy, is caused by airborne pollen which is exacerbated by air pollution, cigarette smoke, certain foods, mold, pet allergens, insects and even chemicals found in clothing and fragrances. When an allergen comes in contact with the eyes, tissue cells release a number of chemicals, including histamine -- a chemical produced in reaction to a substance that the immune system cannot tolerate.

Source: Scripps Clinic

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs